These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 21997371)
1. Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM. Yu J; Parkhitko A; Henske EP Autophagy; 2011 Nov; 7(11):1400-1. PubMed ID: 21997371 [TBL] [Abstract][Full Text] [Related]
2. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis. Feng Y; Mischler WJ; Gurung AC; Kavanagh TR; Androsov G; Sadow PM; Herbert ZT; Priolo C Cancer Res; 2020 Jul; 80(13):2751-2763. PubMed ID: 32393662 [TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors. Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182 [TBL] [Abstract][Full Text] [Related]
5. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447 [TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. Yu J; Parkhitko AA; Henske EP Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM). Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865 [TBL] [Abstract][Full Text] [Related]
8. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Kwiatkowski DJ Lymphat Res Biol; 2010 Mar; 8(1):51-7. PubMed ID: 20235887 [TBL] [Abstract][Full Text] [Related]
9. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development. Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404 [TBL] [Abstract][Full Text] [Related]
10. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells. Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629 [TBL] [Abstract][Full Text] [Related]